Vanguard Therapeutics Inc


Vanguard Therapeutics Inc
Profile last edited on: 1/31/2018

Oral cell adhesion blocking agent: long-term prophylactic therapy for sickle cell disease patients.
Year Founded
First SBIR Year
Latest SBIR Award
Program Status


Is this YOUR Company?
Ensure accuracy and completeness of YOUR Company Profile by completing the brief Survey Instrument attached
Do you know about this Awardees?
Let us encourage you to provide any data which would enhance the completeness of this firm's profile.

Location Information

108 Eagle Trace Drive
Half Moon Bay, CA 94019
   (415) 203-0436
Multiple Locations:   
Congressional District:   14
County:   San Mate

Public Profile

Vanguard Therapeutics, Inc. is an early stage firm developing an orally absorbable cell adhesion-blocking drug for the prophylactic therapy of sickle cell disease. Founded by long-term UCSF facultoy with important pharmaceutical industry experience, program is based on the knowledge that clinical problems of sickle cell disease are the result of abnormal blood flow and that adhesion of sickle red blood cells to the vascular endothelium is fundamental to the abnormal blood flow. P-selectin on vascular endothelial cells is central to sickle red blood cell adhesion, and the firm's compound effectively blocks P-selectin. Firm is addressing development of reliable assays for parent compound and the identification of a superior fraction of that compound for use as an active pharmaceutical ingredient in commercial development. Firm has associate status with JLabs

Extent of SBIR involvement

User Avatar

Synopsis: Awardee Business Condition

Employee Range
Revenue Range
VC funded?
Privately Held
Stock Info
: N/A
IP Holdings

Awards Distribution by Agency

Most Recent SBIR Projects


  Stephen H Embury -- Co-Founder

SBIR firms in the news